EUVIMEDEUVIMED entdecken
Open Access

Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis

Alexandrina Balanean, Cherrishe Brown-Bickerstaff, Andrew Klink iD, Vardhaman Patel iD, Hanke Zheng iD, Laetitia N'Dri, Keith Wittstock iD, Bruce Feinberg iD, Mark Chaballa, Vadim Khaychuk, Jill Kaufman, Prathamesh Pathak und 1 weitere

Journal of Comparative Effectiveness Research · 2024

DOI: 10.57264/cer-2023-0144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Alexandrina Balanean und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardinal Health, Dublin, OH 43017, USA. Hauptthemen laut MEDLINE: Abatacept, Arthritis, Rheumatoid, Antirheumatic Agents, Rheumatoid Factor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

In rheumatoid arthritis (RA), seropositivity for both anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) is associated with disease severity and therapeutic response. Biologic (b) disease-modifying antirheumatic drugs (DMARDs) such as abatacept are recommended after inadequate response or contraindication to conventional synthetic DMARDs. This retrospective cohort study aimed to describe changes in Clinical Disease Activity Index (CDAI) measures over 12 months among patients with ACPA+ and RF+ RA with an inadequate response to methotrexate treated with abatacept as a first-line bDMARD. Patients & methods: Patient data were abstracted from medical records by treating rheumatologists. Analyses included McNemar tests for paired proportions or paired t -tests to assess longitudinal changes in CDAI scores, and Kaplan–Meier methods for time-to-event outcomes. Serious AEs and rationale for initiating treatment were recorded.

Results

Overall, 296 patients were included. Mean CDAI scores improved (decreased) by 34.0, 61.0 and 74.0% (all p < 0.001) from baseline to 3–6 months, 6–12 months and ≥12 months after abatacept initiation, respectively. Of 279 patients not in CDAI low disease activity (LDA) or remission at baseline, 24.7% of patients achieved it within 6 months, 56.3% within 12 months and 71.0% at any point during follow-up after abatacept initiation. Median time to CDAI LDA/remission was 10.2 months. Serious AEs were reported in 2.4% of patients. Common reasons reported by rheumatologists for initiating abatacept were effectiveness/efficacy (52.7%), safety (31.4%) and patient preference (25.3%).

Conclusion

In this analysis of patients with ACPA+ and RF+ RA treated with abatacept as a first-line bDMARD in a clinical practice setting, clinical outcomes and remission rates were improved at all time points, providing real-world evidence to further support the use of abatacept in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptArthritis, RheumatoidAntirheumatic AgentsRheumatoid FactorAnti-Citrullinated Protein AntibodiesHumansRetrospective StudiesMaleMiddle AgedFemaleAgedTreatment OutcomeAdultSeverity of Illness IndexMethotrexate

Stichwörter der Autor:innen

abataceptanticitrullinated protein antibodyfirst-line therapyrheumatoid arthritisrheumatoid factor

Substanzen

AbataceptAntirheumatic AgentsRheumatoid FactorAnti-Citrullinated Protein AntibodiesMethotrexate

Autor:innen und Institutionen

  • Cardinal Health, Dublin, OH 43017, USA.
  • Bristol Myers Squibb, Princeton, NJ 08540, USA.
  • Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC 28207, USA.

ORCID-Profile: Andrew Klink, Vardhaman Patel, Hanke Zheng, Keith Wittstock, Bruce Feinberg

Zitieren

APA

Balanean, A., Brown-Bickerstaff, C., Klink, A., Patel, V., Zheng, H., N'Dri, L., Wittstock, K., Feinberg, B., Chaballa, M., Khaychuk, V., Kaufman, J., Pathak, P., & Lam, G. (2024). Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0144

Vancouver

Balanean A, Brown-Bickerstaff C, Klink A, Patel V, Zheng H, N'Dri L, et al. Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2023-0144

BibTeX
@article{Balanean2024,
  author = {Balanean, Alexandrina and Brown-Bickerstaff, Cherrishe and Klink, Andrew and Patel, Vardhaman and Zheng, Hanke and N'Dri, Laetitia and Wittstock, Keith and Feinberg, Bruce and Chaballa, Mark and Khaychuk, Vadim and Kaufman, Jill and Pathak, Prathamesh and Lam, Gordon},
  title = {Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2024},
  doi = {10.57264/cer-2023-0144}
}
Kostenlos starten →